Abstract
LBA3 - A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc – Updated Progression Free Survival and Duration of Response Data
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have